Diyong Xu Biography and Net Worth

Director of Q32 Bio

Diyong Xu is a Principal on the Private Equity team at OrbiMed, covering venture capital investments in biotech, medical device and diagnostics companies. Diyong has been a board observer for Terns. He was previously a board observer for Arcutis, Imara, NextCure, Passage Bio, Repare and SpringWorks.

Prior to joining OrbiMed, Diyong worked for Lazard in Healthcare Investment Banking Group, where he focused on M&A, financing and strategic advisory for biotech, diagnostics and pharma clients in U.S., Japan and E.U.

Diyong received his M.S. in Management Science and Engineering from Stanford University, M.S. in Molecular and Cellular Biology from Dartmouth College, and B.S. in Biology from Zhejiang University.

What is Diyong Xu's net worth?: The estimated net worth of Diyong Xu is at least $64.67 million as of May 28th, 2026. Xu owns 3,502,987 shares of Q32 Bio stock worth more than $64,665,140 as of July 14th. This net worth estimate does not reflect any other assets that Xu may own. Learn More about Diyong Xu's net worth.
How do I contact Diyong Xu?: The corporate mailing address for Xu and other Q32 Bio executives is ONE PATRIOTS PARK, BEDFORD MA, 01730. Q32 Bio can also be reached via phone at 781-301-7277 and via email at [email protected]. Learn More on Diyong Xu's contact information.
Has Diyong Xu been buying or selling shares of Q32 Bio?: Diyong Xu has not been actively trading shares of Q32 Bio within the last three months. Most recently, on Thursday, May 28th, Diyong Xu bought 1,875,000 shares of Q32 Bio stock. The stock was acquired at an average cost of $8.00 per share, with a total value of $15,000,000.00. Following the completion of the transaction, the director now directly owns 3,502,987 shares of the company's stock, valued at $28,023,896. Learn More on Diyong Xu's trading history.
Who are Q32 Bio's active insiders?: Q32 Bio's insider roster includes Lee Kalowski (PRESIDENT & CHIEF FINANCIAL OFFICER), Jodie Morrison (CEO), and Diyong Xu (Director). Learn More on Q32 Bio's active insiders.
Are insiders buying or selling shares of Q32 Bio?: In the last year, Q32 Bio insiders bought shares 2 times. They purchased a total of 3,750,000 shares worth more than $30,000,000.00. In the last year, insiders at the sold shares 8 times. They sold a total of 66,008 shares worth more than $216,507.14. The most recent insider tranaction occured on May, 28th when Director Diyong Xu bought 1,875,000 shares worth more than $15,000,000.00. Insiders at Q32 Bio own 34.5% of the company. Learn More about insider trades at Q32 Bio.
Information on this page was last updated on 5/28/2026.

Diyong Xu Insider Trading History at Q32 Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/28/2026	Buy	1,875,000	$8.00	$15,000,000.00	3,502,987

Diyong Xu Buying and Selling Activity at Q32 Bio

Q32 Bio Company Overview

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

Today's Range

Now: $18.46

$17.50

$23.57

50 Day Range

MA: $10.54

$5.14

$21.38

2 Week Range

Now: $18.46

$1.57

$23.57

Volume

3,554,888 shs

Average Volume

738,139 shs

Market Capitalization

$313.08 million

P/E Ratio

6.94

Dividend Yield

N/A

Beta

0.24